Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity)
Homodimer; disulfide-linked (By similarity). Also found as heterodimer with PGF (By similarity). Interacts with NRP1 (PubMed:26503042).
Interacts with isoform 2 of BSG (PubMed:25825981). Interacts with CD82; this interaction inhibits VEGFA-mediated signaling pathway (PubMed:34530889)
Higher expression in pituitary tumors than the pituitary gland
Widely expressed
Widely expressed
Widely expressed
Not widely expressed
Not widely expressed
Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults.
It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
| Cancer Type | Mutation Percentage |
|---|---|
| Central Nervous System Astrocytoma Grade Iv | 0.38% |
| Lung Adenocarcinoma | 0.26% |
| Lung Squamous Cell Carcinoma | 0.27% |
| Oesophagus Adenocarcinoma | 0.31% |
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to VEGFA, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 4
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT07375407 | Primary Hypertension, Grade 2 | Aerobic Exercise vs Physiological Ischemic Training in Stage 2 Hypertension | NA | COMPLETED |
| NCT00446381 | Proliferative Diabetic Retinopathy, Diabetic Macular Edema | Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema) | NA | COMPLETED |
| NCT01757223 | Coronary Artery Disease | Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery | PHASE1, PHASE2 | WITHDRAWN |
| NCT02357342 | Age-Related Macular Degeneration | Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD | PHASE2 | COMPLETED |
| NCT02901236 | Glaucoma | Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma | PHASE2, PHASE3 | COMPLETED |
| NCT00827372 | Lymphedema | A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer | PHASE2 | COMPLETED |
| NCT00327444 | Ovarian Neoplasms, Ascites | Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites | PHASE2, PHASE3 | COMPLETED |
| NCT00320788 | Macular Degeneration | Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD) | PHASE2 | COMPLETED |
| NCT03810313 | Central Retinal Vein Occlusion | Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion | PHASE3 | TERMINATED |
| NCT00457145 | Telangiectasia | Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation | PHASE1 | COMPLETED |